Five things for pharma marketers to know: Friday, August 10, 2018

Share this content:

The FDA approved a record number of generics last month. The federal agency approved or tentatively approved 126 generic drugs in July. Observers saw it as a signal that the Trump administration is moving generics through the approval process more quickly, one of the goals of President Donald Trump's drug-pricing blueprint. (Regulatory Focus)

However, generic drugmakers are struggling as the Trump administration pushes for lower drug prices. As the White House opens the market to new drugs to push down branded drug prices, generics are also seeing prices drop. Generic-makers, such as Mylan and Perrigo, are considering changes to their generic businesses as a result. (Bloomberg)

As activist investor Carl Icahn works to stop the merger of Cigna and Express Scripts, Institutional Shareholder Services has recommended that shareholders approve the deal. The advisory firm acknowledged there are potential competition and regulatory risks, but said the benefits outweigh them. (CNBC)

The Justice Department has joined a lawsuit against opioid makers Indivior and Reckitt Benckiser Group. The suit alleges that the drugmakers improperly marketed the opioid-addiction treatment Suboxone. The DOJ said it is intervening in four whistleblower lawsuits brought against the companies. (Reuters)

Amazon plans to pilot employee health clinics at its Seattle headquarters. The company is planning to open a primary-care clinic this year for a group of employees, then expand it early next year. Primary and preventive care is a focus of Atul Gawande, who is leading the healthcare venture from Amazon, Berkshire Hathaway, and JP Morgan Chase. (CNBC)

Share this content:
Scroll down to see the next article